Gross margin for the full-year 2023 is expected to be approximately 84.5%; As of December 31, 2023, approximately $89.1 million in cash, cash equivalents, and marketable securities. “This was a transformative year for AVITA Medical as we focused on accelerating our growth profile,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “We have made tremendous progress over the last four quarters, with consecutive commercial revenue growth rates of 40%, 42%, 51%, and 50%, respectively, over the same periods in 2022. We remain committed to sustaining growth and building our business in 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RCEL:
- AVITA Medical Announces Preliminary 2023 Financial Highlights, Provides 2024 Financial Guidance and Business Update
- AVITA Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- AVITA Medical to Host Investor Webinar Briefing
- AVITA Medical to Present at the Piper Sandler 35th Annual Healthcare Conference
- Avita Medical lowers FY23 revenue view to $49.5M -$50.5M from prior $51M -$53M
